Recent Publications: Editorial Support and/or Authorship

Assunção SS, Sperling RA, Ritchie C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimers Res Ther. 2022;14(1):54. PMID: 35440022

Cooper-Olson G, Rodino-Klapac LR, Potter RA. Evaluation of the lipid-binding properties of recombinant dystrophin spectrin-like repeat domains R1-3. J Neuromuscul Dis. 2021;8(4):489-494. PMID: 33780374

Cummings JL, Ismail Z, Dickerson BC, Ballard C, Grossberg G, McEvoy B, Foff E, Atri A. Development and assessment of a brief screening tool for psychosis in dementia. Alzheimers Dement (Amst). 2021;13(1):e12254. PMID: 34934801

Griffin DA, Pozsgai ER, Heller KN, Potter RA, Peterson EL, Rodino-Klapac LR. Pre-clinical systemic delivery of adeno-associated α-sarcoglycan gene transfer for limb-girdle muscular dystrophy. Hum Gene Ther. 2021;32(7-8):390-404. PMID: 33349138

Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Jackson WC, Small GW, Grossberg GT, Clevenger CK, Cotter V, Stefanacci R, Wise-Brown A, Sabbagh MN. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021 Aug;290(2):310-334. PMID: 33458891

Mendell JR, Khan N, Sha N, Eliopoulos H, McDonald CM, Goemans N, Mercuri E, Lowes LP, Alfano LN; Eteplirsen Study Group. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J Neuromuscul Dis. 2021;8(4):469-479. PMID: 33523015

Mukashyaka MC, Wu CL, Ha K, Zhang J, Wood J, Foley S, Mastis B, Jungels N, Sun H, Shadid M, Harriman S, Hadcock JR. Pharmacokinetic/pharmacodynamic modeling of a cell-penetrating peptide phosphorodiamidate morpholino oligomer in mdx mice. Pharm Res. 2021;38(10):1731-1745. PMID: 34671920

Potter RA, Griffin DA, Heller KN, Peterson EL, Clark EK, Mendell JR, Rodino-Klapac LR. Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther. 2021;32(7-8):375-389. PMID: 333397205

Asher DR, Thapa K, Dharia SD, Khan N, Potter RA, Rodino-Klapac LR, Mendell JR. Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20(3):263-274. PMID:32031420

Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F; SKIP-NMD Study Group. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;26(21):e2270-e2282. PMID: 32139505

Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, Iammarino MA, Alfano LN, Nicholl A, Al-Zaidy S, Lewis S, Church K, Shell R, Cripe LH, Potter RA, Griffin DA, Pozsgai E, Dugar A, Hogan M, Rodino-Klapac LR. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77(9):1122-1131. PMID: 32539076

Schnell FJ, Frank D, Fletcher S, Johnsen RD, Wilton SD. Challenges of interpreting dystrophin content by western blot. US Neurology. 2019;15(1):40-46. Available at: https://www.touchneurology.com/wp-content/uploads/sites/3/2019/04/US-Neuro-15.1_p40-46.pdf

Hanania NA, Braman S, Adamas SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S. The role of inhalation delivery devices in COPD: Perspectives of patients and healthcare providers. Chronic Obstr Pulm Dis. 2018;5(2):111-123. PMID: 30374449

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788-799. PMID: 29486041

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson KJ, Thamlikitkul V, Dudley MN, Redell MA. Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii. International Journal of Antimicrobial Agents. 2018;52(3):404-406. PMID: 29665446

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother. 2018;62(3):e02103-17. PMID: 29311069

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439-455. PMID: 30270406

Lodise TP, Fan W, Griffith DC, Dudley MN, Sulham KA. A retrospective cohort analysis shows that coadministration of minocycline with colistin in critically ill patients is associated with reduced frequency of acute renal failure. Antimicrob Agents Chemother. 2017;62(1):e01165-17. PMID: 29038261

Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O. Potency of meropenem-vaborbactam in lung surfactant. Antimicrob Agents Chemother. 2017;62(1):e01702-17. PMID: